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0.36 (p < 0.001)]. Median survival for patients receiving 
RT (7.0%) was 9.2 months, but this was not significantly 
different from patients receiving BSC (p = 0.068). Patients 
receiving SURG compared to SYST had a longer PFS (9.0 
vs. 4.3 months, respectively; p < 0.001), but no difference 
in OS was observed. After adjustments for confounders, 
patients with rGBM selected for treatment with SURG or 
SYST do survive significantly longer than patients who are 
selected for BSC based on clinical parameters. The value of 
reoperation versus systemic treatment strategies needs fur-
ther investigation.
Keywords Recurrent glioblastoma multiforme · 
Treatment strategies · Treatment effectiveness · Survival 
outcome
Introduction
Glioblastoma multiforme (GBM) is the most common and 
aggressive primary brain tumor in adults. Standard treat-
ment for patients with newly diagnosed GBM consists of 
Abstract Glioblastoma multiforme (GBM) universally 
recurs with dismal prognosis. We evaluated the efficacy 
of standard treatment strategies for patients with recurrent 
GBM (rGBM). From two centers in the Netherlands, 299 
patients with rGBM after first-line treatment, diagnosed 
between 2005 and 2014, were retrospectively evaluated. 
Four different treatment strategies were defined: systemic 
treatment (SYST), re-irradiation (RT), re-resection fol-
lowed by adjuvant treatment (SURG) and best supportive 
care (BSC). Median OS for all patients was 6.5 months, 
and median PFS (excluding patients receiving BSC) was 
5.5 months. Older age, multifocal lesions and steroid use 
were significantly associated with a shorter survival. 
After correction for confounders, patients receiving SYST 
(34.8%) and SURG (18.7%) had a significantly longer sur-
vival than patients receiving BSC (39.5%), 7.3 and 11.0 
versus 3.1 months, respectively [HR 0.46 (p < 0.001) and 
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maximal surgical resection followed by postoperative radi-
ation with concomitant and adjuvant temozolomide therapy 
[1]. Despite this treatment, recurrence is almost inevitable 
and the prognosis remains poor with a median survival of 
12–15 months [2]. At the time of recurrence, treatment 
options are limited with modest activity. Therefore, no 
universally held standard of care is available for recurrent 
GBM (rGBM).
Systemic treatment is commonly suggested for recur-
rence, of which nitrosoureas (e.g. lomustine) are mostly 
used. However, effectiveness of nitrosoureas-based ther-
apy is limited, considering a progression-free survival rate 
at 6 months of 19% and an objective response rate of less 
than 10% [3]. Unfortunately, bevacizumab fails to improve 
overall survival in both newly diagnosed and rGBM set-
ting [4–9]. A temozolomide rechallenge has been studied 
in multiple clinical trials in various schedules with mixed 
results [10–12]. However, recent results suggest that 
patients with a  O6-methylguanine DNA methyltransferase 
(MGMT) promoter-methylated recurrent tumor may benefit 
from a temozolomide rechallenge [13].
Some patients with rGBM undergo re-irradiation, 
which may result in local disease control in a proportion of 
patients [14–18]. However, this approach is not always fea-
sible due to the hazards of cumulative neurotoxicity.
At the time of recurrence, only a small number of 
patients with well-localized tumors are eligible for re-resec-
tion. While the benefits of resecting a newly diagnosed 
glioblastoma have been demonstrated in several studies, the 
benefits of a re-resection remain unclear [19, 20]. Although 
there are no comparative, randomized studies available, 
recent reports suggest the potential benefit of a re-resection 
with an acceptable complication rate [21–23].
Since none of the treatments for recurrence is more ben-
eficial than the other, treatment is based on center-specific 
preferences and patients’ individual characteristics, such as 
age, performance status, tumor location, time to recurrence, 
and corticosteroid use [24, 25]. The aim of this retrospec-
tive analysis was to evaluate currently applied treatment 
strategies for patients with rGBM to get more insight in 
their potential benefit and the optimal approach.
Materials and methods
Patient selection and data collection
This study was approved by the institutional review 
board of the VU University Medical Center Amsterdam 
(VUMC). Permission for the use of anonymized patient 
data was given by the institutional research departments 
of the VUMC and University Medical Center Groningen 
(UMCG).
We retrospectively collected clinical data of patients 
treated at VUMC and UMCG, two specialized medical 
centers for brain tumors in The Netherlands. Patients aged 
18 years and older with rGBM after first-line treatment 
from January 2005 to December 2014 were enrolled. To 
explore the benefit of a re-resection at the time of recur-
rence, only patients with a resection at initial presentation 
were included. Furthermore, patients should have at least 
completed chemoradiation after first-line resection. Exclu-
sion criteria were patients with low-grade or anaplastic gli-
omas, secondary GBM, cerebral metastases or other brain 
lesions. Patient records with insufficient data documented 
or an inadequate follow-up were also excluded.
Eligible patients were grouped according to their treat-
ment: systemic treatment (SYST), surgical re-resection fol-
lowed by systemic treatment and/or re-irradiation (SURG), 
re-irradiation (RT) and best supportive care (BSC). The 
identification and inclusion process is illustrated in Fig. 1.
Outcomes
Overall survival (OS) was defined as the time of objec-
tive tumor recurrence to death or considered censored at 
the end of follow-up. Progression-free survival (PFS) was 
defined as the time of objective tumor recurrence to clinical 
or radiological evidence of progression, death or consid-
ered censored at the end of follow-up.
Clinical variables
Choice of treatment was included in our analyses to explore 
its association with survival. Age, sex, tumor extent, the 
extent of initial resection of contrast-enhanced lesions, 
Karnofsky and ECOG performance scores, corticosteroid 
use and time to recurrence, defined as the operation date at 
the time of diagnosis to the date of objective tumor recur-
rence, were also included in these analyses to investigate 
their association with survival and correct for their poten-
tial confounding effect. Furthermore, the possible interact-
ing effect between these clinical variables and choice of 
therapy were investigated in our analyses. Treatment cent-
ers were considered as strata in the analyses.
Statistical analysis
Differences between treatment groups were evaluated 
using an overall Chi square test for categorical data, 
Kruskal–Wallis ANOVA for ordinal and continuous data, 
and the log-rank test for censored time-to-event data. Post 
hoc tests with Bonferroni correction were performed to 
evaluate pairwise differences between treatment groups 
in case of a significant overall effect between treatment 
groups. The Kaplan–Meier method was used to calculate 
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the median OS and PFS and to produce survival curves. 
The Cox proportional hazards model was used as an 
univariate analysis to determine significant differences 
between treatment groups, followed by a multivariate 
Cox regression analysis to adjust for confounders and 
possible interacting effects. Furthermore, hazard ratios 
(HRs) for the treatment groups and clinical variables 
were calculated and reported with 95% confidence inter-
vals. Treatment centers were considered as strata in the 
Fig. 1  Flow chart
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Cox regression analysis. For all statistical analyses IBM 
SPSS Statistics, version 22, was used.
Results
Patients
A total of 681 patients with GBM were initially identi-
fied in both centers. Subsequent to reviewing the records, 
299 eligible patients were included in our analyses. Main 
reasons for exclusion were insufficiently documented data 
(21.0%), no resection at initial presentation (13.5%) or no 
documented recurrence (9.7%).
Patient characteristics are summarized in Table  1. All 
patients completed chemoradiation during first-line treat-
ment. Treatment groups differed significantly in regard to 
patients’ age with a median age of 62 years for the patients 
in the BSC group, compared to 56 years in the SURG 
group and 59 years in both the SYST and RT groups (over-
all p = 0.041). However, post hoc tests with Bonferroni cor-
rection did not reveal specific pairs of treatment groups that 
differed significantly. The percentage of men was not sig-
nificantly different between treatment groups (p = 0.106). 
The rate of complete initial resections of contrast-enhanced 
lesions was significantly higher in the SURG group com-
pared to the BSC group (post hoc p < 0.001). The time to 
recurrence significantly differed between treatment groups 
(overall p < 0.001). Post hoc test showed a significantly 
shorter time to recurrence for patients in the BSC group, 
a median of 263 days, compared to 376 days in the SYST 
group, 474 days in the SURG group and 554 days in the RT 
group (post hoc p < 0.001). ECOG and KPS performance 
status significantly differed between treatment groups 
(overall p < 0.001). Post hoc analyses showed worse per-
formance scores in the BSC groups compared to all other 
treatment groups (post hoc p < 0.001). The performance 
scores between the SYST, SURG and RT groups did not 
significantly differ. In addition, corticosteroids were more 
frequently used in the BSC group in comparison to the 
other groups (post hoc p ≤ 0.001). Furthermore, patients in 
the SURG group used corticosteroids less frequently com-
pared to patients in the SYST group (post hoc p = 0.003). 
The median corticosteroid dose in the SYST group, 4 mg/
day, was significantly lower than the median dose in the 
BSC group (6  mg/day; post hoc p = 0.003). Lastly, anti-
epileptic drugs were used at similar rates in all treatment 
groups (overall p = 0.445).
Treatment outcomes for all patients
In Fig.  2 the survival curves for OS (A) and PFS (B) for 
the different treatment groups are depicted. Since follow-up 
data (e.g. radiological evaluation) for patients with best 
supportive care were unavailable, they were excluded from 
our PFS analysis. PFS and OS were significantly different 
for the treatment groups after stratification for both treat-
ment centers (log-rank test; p < 0.001).
At the end of our follow-up, 7 patients (6.7%) in SYST 
group, 10 patients (17.9%) in SURG group, 2 patients 
(9.5%) in RT group and 3 patients (2.5%) in BSC group 
were still alive. The median OS for patients in the BSC 
group was 3.1 months (95% CI 2.6–3.5 months) compared 
to 7.3 months (95% CI 6.0–8.5 months) in the SYST group, 
11.0 months (95% CI 8.2–13.8 months) in the SURG group 
and 9.2 months (95% CI 6.6–11.8 months) in the RT group.
In Table 2 the hazard ratios (HRs) of death are described 
for our analysis of OS using an univariate and multivari-
ate Cox proportional hazards model with stratification for 
treatment center. In our univariate analysis overall survival 
did significantly differ between treatment arms (overall 
p < 0.001), with a longer OS in SYST, SURG and RT com-
pared to the BSC group (post hoc p < 0.001 for all groups). 
Furthermore, univariate analyses of age, sex, tumor extent, 
extent of initial resection, performance status, time to 
recurrence and steroid use all showed significant associa-
tions with overall survival (p = 0.029, p = 0.001, p = 0.002, 
p = 0.017, p < 0.001, p < 0.001 and p < 0.001, respectively). 
Therefore, these clinical variables were included as covari-
ates in our multivariate Cox model to correct for a possible 
confounding effect. Univariate analysis of tumor location 
(e.g. frontal, parietal, temporal or occipital lesions) showed 
no significant correlation with survival and was therefore 
excluded from our multivariate analyses (p = 0.100). After 
adjustment for the confounders, patients in the SYST group 
and SURG group still had a significantly prolonged sur-
vival compared to the BSC group with adjusted hazard 
ratios of 0.46 (95% CI 0.33–0.66; p < 0.001) and 0.36 (95% 
CI 0.23–0.58; p < 0.001), respectively. The survival benefit 
of the re-irradiation group over BSC was not significantly 
different after adjustment for confounders (HR = 0.60; 95% 
CI 0.34–1.04; p = 0.068). In addition to these findings, 
there was no significant difference in survival between the 
SURG and SYST group (p = 0.241). None of our clinical 
variables had an interacting effect with choice of treatment 
on survival.
Based on 175 patients from the SYST, SURG and RT 
groups included in our analysis of PFS, 1 patient (1.0%) 
in the SYST group, 6 patients (10.7%) in the SURG 
group and 1 patient (4.8%) in the RT group had no evi-
dence of progression at the end of our follow-up. For 12 
of the 167 patients that showed progression (7.2%), the 
date of progression was defined as date of death. Median 
PFS for patients in the SYST group was 4.3 months (95% 
CI 3.0–5.6 months) compared to 9.0 months (95% CI 
6.8–11.3 months) in the SURG group and 7.7 months 
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Table 1  Demographic and clinical characteristics of all patients
Factor Total study population (n = 299)
Systemic treat-
ment (n = 104)
Surgical reinterven-
tion (n = 56)
Re-irradiation (n = 21) Best supportive 
care (n = 118)
P value
Age (years) 0.041
 Mean 56 55 57 60
 Median 59 56 59 62
 Range 19–77 26–74 26–71 21–85
Age (no) 0.511
 ≤ 50 26 (25.0%) 18 (32.1%) 5 (23.8%) 23 (19.5%)
 51–65 55 (52.9%) 27 (48.2%) 10 (47.6%) 59 (50.0%)
 > 65 23 (22.1%) 11 (19.6%) 6 (28.6%) 36 (30.5%)
Gender (no) 0.106
 Male 71 (68.3%) 43 (76.8%) 10 (47.6%) 78 (66.1%)
 Female 33 (31.7%) 13 (23.2%) 11 (52.4%) 40 (33.9%)
Tumor location (no) 0.182
 Frontal lobe 28 (26.9%) 21 (37.5%) 6 (28.6%) 39 (33.1%)
 Parietal lobe 17 (16.3%) 5 (8.9%) 4 (19.0%) 12 (10.2%)
 Occipital lobe 6 (5.8%) 0 (0.0%) 0 (0.0%) 3 (2.5%)
 Temporal lobe 22 (21.2%) 16 (28.6%) 7 (33.3%) 25 (21.2%)
 Multiple lobes 30 (28.8%) 13 (23.2%) 2 (9.5%) 34 (28.8%)
 Other 1 (1.0%) 1 (1.8%) 2 (9.5%) 5 (4.2%)
Tumor extent (no) 0.257
 Single lobe 74 (71.2%) 43 (76.8%) 19 (90.5%) 84 (71.2%)
 Multiple lobes 30 (28.8%) 13 (23.2%) 2 (9.5%) 34 (28.8%)
Extent of initial resection (no) 0.004
 Complete 27 (26.0%) 23 (41.1%) 4 (19.0%) 20 (16.9%)
 Incomplete 67 (64.4%) 26 (46.4%) 15 (71.4%) 93 (78.8%)
 Unknown 10 (9.6%) 7 (12.5%) 2 (9.5%) 5 (4.2%)
Adjuvant Temozolomide cycles (no) <0.001
 Mean 6 5 5 4
 Median 6 6 6 5
 Range 1–6 0–12 0–6 0–12
Karnofsky performance status (no) <0.001
 100–90 42 (40.4%) 25 (44.6%) 7 (33.3%) 4 (3.4%)
 80–70 49 (47.1%) 29 (51.8%) 10 (47.6%) 37 (31.4%)
 60–50 11 (10.6%) 2 (3.6%) 4 (19.0%) 39 (33.1%)
 40–30 2 (1.9%) 0 (0.0%) 0 (0.0%) 38 (32.2%)
ECOG performance score (no) <0.001
 0 39 (37.5%) 20 (35.7%) 6 (28.6%) 3 (2.5%)
 1 53 (51.0%) 30 (53.6%) 11 (52.4%) 35 (29.7%)
 2 9 (8.7%) 6 (10.7%) 4 (19.0%) 37 (31.4%)
 3 3 (2.9%) 0 (0.0%) 0 (0.0%) 43 (36.4%)
Time to recurrence (days) <0.001
 Mean 459 595 598 323
 Median 376 474 554 263
 Range 113–2097 71–1540 259–1733 59–1453
Use of steroids (no) <0.001
 Yes 61 (58.7%) 18 (32.1%) 11 (52.4%) 94 (79.7%)
 No 42 (40.4%) 35 (62.5%) 10 (47.6%) 17 (14.4%)
 Unknown 1 (1.0%) 3 (5.4%) 0 (0.0%) 7 (5.9%)
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(95% CI 1.8–13.5 months) in the RT group. A significant 
difference in progression-free survival was seen between 
treatment groups (overall p < 0.001; see Supplemen-
tary Table  S1). Patients in the SURG group had a pro-
longed progression-free survival compared to patients in 
the SYST group, but not compared to patients receiving 
re-irradiation (post hoc p < 0.001 and p = 0.176, respec-
tively). The difference compared to SYST remained sig-
nificant after correction for confounders with an adjusted 
HR of 0.37 (95% CI 0.23–0.59; p < 0.001). However, 
Table 1  (continued)
Factor Total study population (n = 299)
Systemic treat-
ment (n = 104)
Surgical reinterven-
tion (n = 56)
Re-irradiation (n = 21) Best supportive 
care (n = 118)
P value
Daily steroid dose (mg) 0.018
 Mean 5 6 5 6
 Median 4 6 3 6
 Range 1–12 0–12 1–16 1–20
Use of antiepileptic drugs (no) 0.445
 Yes 58 (55.8%) 34 (60.7%) 11 (52.4%) 73 (61.9%)
 No 46 (44.2%) 20 (35.7%) 9 (42.9%) 43 (36.4%)
 Unknown 0 (0.0%) 2 (3.6%) 1 (4.8%) 2 (1.7%)
Extent of second resection (no)
 Complete – 16 (28.6%) – –
 Incomplete – 40 (71.4%) – –
Systemic treatment at recurrence (no) 0.032
 Lomustine 42 (40.4%) 18 (39.1%) – –
 Lomustine + bevacizumab 13 (12.5%) 0 (0.0%) – –
 Temozolomide 14(13.5%) 13 (28.3%) – –
 Bevacizumab 9 (8.7%) 1 (2.2%) – –
 PCV 11 (10.6%) 5 (10.9%) – –
 Other 15 (14.4%) 9 (19.6%) – –
Fig. 2  Kaplan–Meier curves of a overall survival and b progression-free survival for all patients
189J Neurooncol (2017) 135:183–192 
1 3
PFS did not differ between the SYST and RT groups 
(p = 0.390).
Center‑specific outcomes
Table 3 summarizes patient data according to correspond-
ing treatment groups and the median survival outcomes 
per treatment center. In VUMC significantly more patients 
received a re-resection prior to adjuvant treatment (25.7 vs. 
8.9%; p < 0.001) and in UMCG significantly more patients 
underwent re-irradiation (14.5 vs. 1.7%; p < 0.001). Median 
OS were similar for both centers, 5.8 months (95% CI 
4.6–7.0 months) versus 7.1 months (95% CI 6.5–7.7 
months) in VUMC and UMCG, respectively (p = 0.398; see 
Supplementary figure S1). The median PFS in VUMC was 
5.5 months (95% CI 3.9–7.0) compared to 6.2 months (95% 
CI 4.5–7.9) in UMCG.
Subgroup analysis: patients completing post‑operative 
chemoradiation and adjuvant temozolomide
Subgroup analyses were performed in patients that com-
pleted chemoradiation and at least six adjuvant cycles of 
temozolomide after maximal surgical resection (i.e. the 
Stupp regimen). Survival outcomes were almost compa-
rable for this homogenous subgroup of 199 patients (see 
Supplementary figure S2A and 2B; Supplementary tables 
S2 and S3). However, an important finding was that com-
pleted Stupp patients in the RT group had a prolonged sur-
vival compared to the BSC group, even after adjustment for 
Table 2  Cox proportional 
hazards model of overall 
survival after adjustments for 
confounders
Factor Study population (n = 299)
No. of events/no. of 
patients
HR (95% CI) P value
Univariate
 Treatment groups <0.001
  Best supportive care 113/118 1
  Systemic treatment 97/104 0.31 (0.23–0.42)
  Surgical reintervention 46/56 0.20 (0.13–0.29)
  Re-irradiation 19/21 0.28 (0.17–0.46)
Multivariate analysis
 Treatment groups <0.001
  Best supportive care 113/118 1
  Systemic treatment 97/104 0.46 (0.33–0.66)
  Surgical reintervention 46/56 0.36 (0.23–0.58)
  Re-irradiation 19/21 0.60 (0.34–1.04)
 Age (years) – 1.01 (1.00–1.02) 0.019
  Sex 0.002
   Male 192/202 1
   Female 83/97 0.64 (0.49–0.85)
 Tumor extent 0.002
  Single lobe 201/220 1
  Multiple lobes 74/79 1.57 (1.18–2.10)
 Extent of initial resection 0.878
  Incomplete 185/201 1
  Complete 67/74 0.98 (0.73–1.32)
 Recurrence-free interval (days) – 0.999 (0.999–1.00) 0.048
 ECOG performance score 0.124
  0 57/68 1
  1 119/129 1.24 (0.86–1.81)
  2 55/56 1.61 (1.01–2.58)
  3 44/46 1.83 (1.06–3.16)
 Use of steroids 0.001
  No 87/104 1
  Yes 179/184 1.85 (1.33–2.59)
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confounders (p = 0.005). No statistical difference was seen 
between the SYST, SURG and RT treatment groups.
Discussion
In this retrospective analysis of currently applied, second-
line therapies, we provide a better insight in the clinical 
outcome of patients with rGBM. OS between the different 
treatment strategies (i.e. systemic treatment, re-irradiation 
or a surgical re-intervention followed by adjuvant therapy) 
did not differ significantly. As expected from other analy-
ses, older age, tumor extent to multiple lobes and steroid 
use were significantly associated with a shorter survival. In 
addition, patients with rGBM undergoing SYST and SURG 
had a significantly longer survival compared to patients 
receiving BSC. The survival benefit of the RT group over 
BSC was not significantly different from patients receiv-
ing BSC, which may be due to the small size of the group. 
However, a subgroup analysis of patients completing the 
Stupp regimen did show a favorable survival outcome for 
RT patients compared to the BSC group. No survival ben-
efit of SURG compared to SYST was detected, but patients 
receiving SURG compared to SYST did have a prolonged 
PFS. These findings are in line with the results of previous 
studies in which treatment outcomes were compared to best 
supportive care [25, 26].
Our results raise some important and new questions 
for further research. First of all, whether or not to per-
form a re-resection prior to adjuvant therapy, such as sys-
temic treatment or re-irradiation, needs further prospec-
tive evaluation to better determine the actual benefits. In 
several other retrospective studies, either a prolonged sur-
vival of patients with rGBM following a second surgery 
[21–23, 27, 28], or no survival benefit after a re-resection 
for recurrence were reported [25, 29, 30]. In our analysis, 
a prolonged PFS was seen for patients in the SURG 
group compared to patients in the SYST group (9.0 vs. 
4.3 months). Nonetheless, no statistical difference was 
seen in the OS of patients undergoing a re-resection 
prior to adjuvant treatment compared to patients with 
systemic treatment alone. Therefore, it is of high inter-
est to accurately determine in a prospective trial to what 
extent survival can be increased by a re-resection and 
how it would affect the quality of life (QoL) of patients 
with rGBM. Until significantly better treatment options 
become available, QoL data are of crucial importance in 
shared decision making for patients with such a detrimen-
tal prognosis.
At present, there is no standard treatment strategy for 
patients with rGBM. Due to this lack of an universally held 
standard, there are national and international differences 
between the treatment approaches of various treatment 
centers. In our analyses, we compared the outcomes of the 
different treatment strategies used in two university medical 
centers, both specialized in the multidisciplinary treatment 
of brain tumors. Despite some expert-based preferences in 
treatment strategies (SURG vs. RT), our analysis does not 
reveal a significant difference in survival of patients from 
either center.
This is one of the few, recent retrospective analyses in 
which a multivariate strategy has been used to determine 
the treatment outcomes of different treatment modalities 
for a large group of patients with recurrent glioblastoma. 
However, the few retrospective analyses available did not 
compare the outcomes of the different salvage therapies to 
best supportive care [31, 32]. Furthermore, second-line sys-
temic treatment in these studies consisted mostly or solely 
of a rechallenge with temozolomide, while the majority of 
the patients in our analysis (48.7%) received nitrosoureal 
derivatives, the most commonly used second-line chemo-
therapeutical for rGBM.
Table 3  Center-specific outcomes
Factor Total study population (n = 299)
VU Medical Center University Medical Center Groningen Both centers
Proportion of patients (no) 175/299 (58.5%) 124/299 (41.5%) 299/299 (100%)
Treatment groups (no)
 Best supportive care 66 (37.7%) 52 (41.9%) 118 (39.5%)
 Systemic treatment 61 (34.9%) 43 (34.7%) 104 (34.8%)
 Surgical reintervention 45 (25.7%) 11 (8.9%) 56 (18.7%)
 Re-irradiation 3 (1.7%) 18 (14.5%) 21 (7.0%)
 Median OS of all patients (95% CI) 5.8 months [4.6–7.0 months] 7.1 months [6.5–7.7 months] 6.5 months [5.7–7.4 months]
 Median OS, excluding Best supportive 
care (95% CI)
7.7 months [6.0–9.3 months] 10.0 [6.8–13.2 months] 8.5 months [6.9–10.1 months]
 Median PFS, excluding Best supportive 
care (95% CI)
5.5 months [3.9–7.0 months] 6.2 months [4.5–7.9 months] 5.5 months [4.4–6.5 months]
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An important limitation in the analysis of treatment 
outcomes of patients with rGBM is that patient’ charac-
teristics tend to be not evenly distributed among treat-
ment groups. This is inevitable and mainly due to the fact 
that variables, such as age, performance status and tumor 
extent, influence therapeutic decision making in clinical 
practice. Therefore, patients undergoing surgical resec-
tion tend to have better performance status and use cor-
ticosteroids less frequently. In our multivariate analysis, 
we corrected for the confounding effect of these clinical 
relevant variables as much as possible. However, some 
degree of selection bias is inevitable, and therefore our 
results should be interpreted with some caution. Another 
limitation is that data on molecular characteristics, such 
as the MGMT methylation status, were not evaluated. 
Unfortunately, the MGMT promoter status in this group 
of patients is not tested on a routine basis in the Nether-
lands, because of its minimal relevance in clinical deci-
sion making. The MGMT methylation status may predict 
the response to alkylating agents, and may have more 
prognostic value than performance status or other tumor 
characteristics [13, 33, 34].
In prior reports, patients with different grades of glio-
mas, such as anaplastic astrocytoma (WHO grade III) or 
glioblastomas dedifferentiated from a low-grade glioma 
(secondary glioblastoma) were included. Due to higher 
prevalence of favorable mutations, such as the isocitrate 
dehydrogenase 1/2 (IDH1/2) gene mutations, the progno-
sis and survival for these patients are slightly better than 
for patients with de novo (primary) glioblastoma [35–37]. 
To prevent influence of heterogeneity on the analysis, we 
excluded all other types of glioma. This could explain the 
slightly different survival data as compared to other stud-
ies investigating all rGBM diagnoses [29, 38].
In conclusion, we here performed a retrospective, 
multivariate analysis evaluating treatment outcomes of 
patients with rGBM treated in two referral university 
medical centers for brain tumors over a period of nearly 
10 years. After adjustments for the confounders of older 
age, multifocal lesions and steroid use, patients with 
rGBM selected for treatment with SURG or SYST do sur-
vive significantly longer than patients who are selected 
for BSC based on clinical parameters. The additional 
value of specific treatments such as re-resection, sys-
temic treatment or re-irradiation alone remains unclear. 
The true value of reoperation versus systemic treatment 
and how it affects QoL needs further investigation in a 
prospective, randomized trial to what extent a re-resec-
tion can increase survival. In addition, the modest ben-
efit from second-line treatment for patients with rGBM 
clearly provokes the urgent need for innovative treatment 
strategies that have significant impact on their QoL and 
survival.
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